Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
| Autor: | Gardiner, Bradley J, Nierenberg, Natalie E, Chow, Jennifer K, Ruthazer, Robin, Kent, David M, Snydman, David R |
|---|---|
| Předmět: |
CYTOMEGALOVIRUS disease diagnosis
CYTOMEGALOVIRUS disease treatment BIOMARKERS CONFIDENCE intervals CYTOMEGALOVIRUS diseases HEART transplantation KIDNEY transplantation LIVER transplantation LONGITUDINAL method MULTIVARIATE analysis STATISTICS SURGICAL complications T cells TRANSPLANTATION of organs tissues etc. DISEASE relapse TREATMENT effectiveness PROPORTIONAL hazards models RETROSPECTIVE studies LYMPHOCYTE count ODDS ratio |
| Zdroj: | Clinical Infectious Diseases; 11/1/2018, Vol. 67 Issue 9, p1395-1402, 8p |
| Abstrakt: | Background Recurrent cytomegalovirus (CMV) disease in solid organ transplant recipients frequently occurs despite effective antiviral therapy. We previously demonstrated that patients with lymphopenia before liver transplantation are more likely to develop posttransplant infectious complications including CMV. The aim of this study was to explore absolute lymphocyte count (ALC) as a predictor of relapse following treatment for CMV disease. Methods We performed a retrospective cohort study of heart, liver, and kidney transplant recipients treated for an episode of CMV disease. Our primary outcome was time to relapse of CMV within 6 months. Data on potential predictors of relapse including ALC were collected at the time of CMV treatment completion. Univariate and multivariate hazard ratios (HRs) were calculated with a Cox model. Multiple imputation was used to complete the data. Results Relapse occurred in 33 of 170 participants (19.4%). Mean ALC in relapse-free patients was 1.08 ± 0.69 vs 0.73 ± 0.42 × 103 cells/μL in those who relapsed, corresponding to an unadjusted hazard ratio of 1.11 (95% confidence interval, 1.03–1.21; P =.009, n = 133) for every decrease of 100 cells/μL. After adjusting for potential confounders, the association between ALC and relapse remained significant (HR, 1.11 [1.03–1.20]; P =.009). Conclusions Low ALC at the time of CMV treatment completion was a strong independent predictor for recurrent CMV disease. This finding is biologically plausible given the known importance of T-cell immunity in maintaining CMV latency. Future studies should consider this inexpensive, readily available marker of host immunity. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|